In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Kyverna Therapeutics Inc’s stock clocked out at $6.75, down -5.86% from its previous closing price of $7.17. In other words, the price has decreased by -$5.86 from its previous closing price. On the day, 0.79 million shares were traded. KYTX stock price reached its highest trading level at $7.68 during the session, while it also had its lowest trading level at $6.66.
Ratios:
To gain a deeper understanding of KYTX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.39 and its Current Ratio is at 5.39. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.01.
On May 27, 2025, H.C. Wainwright Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $5.
On October 10, 2024, UBS started tracking the stock assigning a Buy rating and target price of $13.UBS initiated its Buy rating on October 10, 2024, with a $13 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KYTX now has a Market Capitalization of 291908256 and an Enterprise Value of 86149256.
Stock Price History:
The Beta on a monthly basis for KYTX is 3.88, which has changed by 0.3803681 over the last 52 weeks, in comparison to a change of 0.19088471 over the same period for the S&P500. Over the past 52 weeks, KYTX has reached a high of $8.45, while it has fallen to a 52-week low of $1.78. The 50-Day Moving Average of the stock is 22.05%, while the 200-Day Moving Average is calculated to be 91.29%.
Shares Statistics:
It appears that KYTX traded 543.97K shares on average per day over the past three months and 831790 shares per day over the past ten days. A total of 43.24M shares are outstanding, with a floating share count of 21.32M. Insiders hold about 50.70% of the company’s shares, while institutions hold 25.38% stake in the company. Shares short for KYTX as of 1760486400 were 1577306 with a Short Ratio of 2.90, compared to 1757894400 on 1608183. Therefore, it implies a Short% of Shares Outstanding of 1577306 and a Short% of Float of 6.35.
Earnings Estimates
A detailed examination of Kyverna Therapeutics Inc (KYTX) is currently in progress, with 5.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.6 and low estimates of -$1.04.
Analysts are recommending an EPS of between -$3.35 and -$4.04 for the fiscal current year, implying an average EPS of -$3.78. EPS for the following year is -$3.5, with 5.0 analysts recommending between -$2.96 and -$4.21.
